Equities analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will report sales of $461.36 million for the current quarter, according to Zacks. Eight analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the highest sales estimate coming in at $490.40 million and the lowest estimate coming in at $449.47 million. Jazz Pharmaceuticals posted sales of $436.40 million in the same quarter last year, which suggests a positive year over year growth rate of 5.7%. The company is scheduled to report its next earnings results on Tuesday, February 26th.
On average, analysts expect that Jazz Pharmaceuticals will report full-year sales of $1.88 billion for the current financial year, with estimates ranging from $1.86 billion to $1.92 billion. For the next year, analysts anticipate that the firm will report sales of $2.07 billion, with estimates ranging from $1.99 billion to $2.19 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.32 by $0.26. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. The company had revenue of $469.37 million during the quarter, compared to analyst estimates of $482.64 million. During the same quarter in the previous year, the firm posted $3.22 EPS. The firm’s quarterly revenue was up 14.0% on a year-over-year basis.
A number of research analysts have issued reports on the company. Leerink Swann boosted their price target on Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, August 17th. BidaskClub upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 28th. Morgan Stanley set a $168.00 price target on Jazz Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 28th. Zacks Investment Research reiterated a “hold” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, November 13th. Finally, Mizuho reiterated a “neutral” rating and set a $173.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, October 15th. Six equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $189.76.
In other news, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction on Friday, September 14th. The stock was sold at an average price of $165.20, for a total value of $33,040.00. Following the completion of the sale, the executive vice president now owns 25,372 shares in the company, valued at $4,191,454.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Matthew P. Young sold 700 shares of the company’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $162.70, for a total value of $113,890.00. Following the completion of the sale, the chief financial officer now owns 33,468 shares of the company’s stock, valued at approximately $5,445,243.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,600 shares of company stock valued at $1,063,472. Insiders own 3.90% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 64.0% during the second quarter. BlackRock Inc. now owns 4,372,080 shares of the specialty pharmaceutical company’s stock valued at $753,311,000 after purchasing an additional 1,706,417 shares during the last quarter. FMR LLC lifted its holdings in shares of Jazz Pharmaceuticals by 12.1% during the second quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock valued at $1,143,203,000 after purchasing an additional 715,595 shares during the last quarter. AGF Investments Inc. purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at $78,345,000. Voya Investment Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at $70,215,000. Finally, Fiera Capital Corp purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at $54,662,000. Institutional investors and hedge funds own 91.53% of the company’s stock.
JAZZ stock traded down $2.33 during trading on Monday, reaching $141.17. 975,543 shares of the company’s stock were exchanged, compared to its average volume of 729,139. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.16 and a current ratio of 4.29. Jazz Pharmaceuticals has a 1-year low of $130.15 and a 1-year high of $184.00. The firm has a market capitalization of $8.66 billion, a PE ratio of 14.77, a price-to-earnings-growth ratio of 0.86 and a beta of 0.94.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Article: Return on Investment (ROI) Defined, Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.